ABSTRACT

Two experiments were carried out during the breeding season in ewes, first to investigate the effects of oral administration of a 3β-hydroxysteroid dehydrogenase (3β-HSD) inhibitor (epostane) on the number of corpora lutea, and secondly to investigate the mechanism through which epostane acts.

In the first experiment Dorset Horn ewes were treated orally with 25, 50, 100 or 200 mg epostane twice daily between days 10 and 15 of the oestrous cycle. All doses of epostane resulted in an increase in the number of corpora lutea per ewe, although the response was curvilinear, with the 25 mg dose showing the largest response and the 200 mg group the smallest response. Although there was no difference between groups in the number of ewes showing oestrus, the higher doses of epostane had a detrimental effect on fertility.

In the second experiment Welsh Mountain ewes were treated twice daily with 25 mg epostane from day 10 of the oestrous cycle and the ovaries were removed for analysis during either the luteal or the follicular phases. Treatment significantly increased the number of follicles >6 mm in diameter, but significantly reduced in-vitro follicular oestradiol and testosterone production. Despite a marked increase in peripheral inhibin concentrations there was no effect on in-vitro inhibin production. Epostane treatment also caused a significant reduction in peripheral FSH concentrations and an increase in mean LH concentration. The latter was due to an increase in LH pulse frequency during the luteal phase and LH pulse amplitude during the follicular phase.

These results confirm that treatment of ewes with epostane orally has a significant effect on follicular steroidogenesis and causes a significant increase in the number of corpora lutea per ewe. This effect on ovulation rate is not via an increase in peripheral FSH concentration, but may be caused by a reduction in follicular steroid activity either directly on the ovary or via an alteration in the pattern of LH secretion.

Journal of Endocrinology (1992) 134, 115–125

ABSTRACT

Immunoreactive α-inhibin (ir-inhibin) was measured in luteal homogenates and subcellular fractions of ovine and porcine corpora lutea (CL) and in pig granulosa cells (GCs), using a sensitive radioimmunoassay specific for the 1–26 amino acid sequence of the N-terminus of the α chain of porcine inhibin (p1–26 α-inhibin). Inclusion of N-ethylmaleimide (N-EM) and/or EDTA in the immunoassay had no effect on the measurement of p1–26 α-inhibin peptide standards, on ir-inhibin levels in ovine follicular fluid and serum, or on ir-inhibin in subcellular fractions of pig GC. Fractionation of porcine GC homogenates on sucrose gradients demonstrated a major particular peak of ir-inhibin (buoyant density, 1·15–1·21 g/cm³) with variable activity in the cytosol. The particulate ir-inhibin peak was released into the cytosol by pretreatment of GC homogenates with the saponin, digitonin, prior to fractionation. Porcine GC extracts contained a protein (M _r 45 000) which immunoblotted against p1–26 α-inhibin antibody.

In the absence of inhibitors of proteolysis, apparent ir-inhibin activity was very high in extracts of sheep and pig CL. However, inclusion of N-EM or EDTA in the radioimmunoassay significantly reduced ir-inhibin levels in porcine and ovine CL extracts in a dose-dependent manner. Measurements of peptide tracer integrity indicated that porcine luteal cytosol degraded ¹²⁵I-labelled p1–26 α-inhibin peptide. Subcellular fractionation studies demonstrated high levels of apparent ir-inhibin in luteal cytosol fractions, with only minor activity peaks associated with particulate fractions; however, this material was not releasable by digitonin. Immunoblotting of detergent extracts of porcine luteal particulate fractions failed to demonstrate α-inhibin material, and immunocytochemical localization studies of α-inhibin in porcine and ovine luteal sections were negative.

Our results are consistent with the intracellular packaging/storage of a form of α-inhibin (M _r similar to that of α-inhibin subunit precursor) in the porcine granulosa cell. However, luteinization of the porcine follicle was associated with a dramatic fall in ir-inhibin content, and the loss of immunostaining for α-inhibin peptides. We conclude that porcine and ovine CL contain little, if any, authentic inhibin. These studies emphasize the importance of excluding proteolytic artefacts when measuring biological peptides in luteal tissue extracts by radioimmunoassay.

Journal of Endocrinology (1992) 134, 341–352

IGFs regulate gonadotrophin-stimulated proliferation and differentiation of granulosa and theca cells in vitro. However, the detailed pattern of mRNA expression of IGFs in bovine follicles remains controversial. The objectives of this study were therefore to describe the temporal and spatial pattern of expression of mRNA encoding IGF-I, IGF-II and the type 1 IGF receptor in bovine follicles in vivo. The expression of mRNA encoding IGF-II was detected in theca tissue from around the time of antrum formation up to and during the development of dominance. No IGF-II mRNA expression was detected in granulosa cells. In the majority of follicles we were unable to detect mRNA encoding IGF-I in either granulosa or theca tissue from follicles at any stage of development. Occasionally low amounts of mRNA encoding IGF-I were detected in the theca externa and connective tissue surrounding some follicles. Type 1 IGF receptor mRNA was detected in both granulosa and theca cells of preantral and antral follicles. Expression was greater in granulosa tissue compared with theca tissue. We also measured IGF-I and -II mRNA in total RNA isolated from cultured granulosa and theca cells using reverse transcriptase PCR. In contrast to the in vivo results, IGF-II mRNA was detected in both granulosa and theca tissue. IGF-I mRNA was detected in theca tissue and in very low amounts in granulosa cells. Using a specific IGF-I RIA we were unable to detect IGF-I immunoreactivity in granulosa conditioned cell culture media. Using immunohistochemistry we detected IGF-I immunoreactivity in some blood vessels within the ovarian stroma. We conclude from these results that IGF-II is the principal intrafollicular IGF ligand regulating the growth of bovine antral follicles. In preantral follicles the expression of mRNA encoding type 1 IGF receptor but absence of endogenous IGF-I or -II mRNA expression, highlights a probable endocrine mechanism for the IGF regulation of preantral follicle growth.

ABSTRACT

We have determined the effect of human insulin-like growth factor-binding protein-1 (hIGFBP-1) on the circulating half-life (t _½) of human insulin-like growth factor-I (hIGF-I) and on hIGF-I-stimulated 2-deoxyglucose uptake in tissues of the cannulated conscious rat. The levels of hIGF-I in rat serum were measured by radioimmunoassay. The assay was carried out in the presence of partially purified rat IGF to remove interference from any IGFBPs not removed by acid–ethanol extraction. An intravenous bolus of 12·5 μg hIGF-I, given to 12-h fasted rats, disappeared from the circulation in a double exponential fashion with an initial t _½ of 1·2±0·2 min (n = 8), which increased to 5·3 ±0·9 min when 100 μg hIGFBP-1 was co-administered (n = 5; P <0·001). The second phase of disappearance of hIGF-I indicated an apparent t _½ of 35·7±5·6 min which was not significantly altered by the co-infusion of hIGFBP-1. Circulating hIGFBP-1, measured with a primate-specific radioimmunoassay, disappeared in a single exponential fashion with a t _½ of 8·8±0·7 min. A tracer amount of 2-deoxy-[1-³H]glucose was administered intravenously at the same time as the peptide(s) and the rate of tissue uptake and phosphorylation of 2-deoxy-[1-³H]glucose determined. Compared with a control group (n = 4), hIGF-I significantly stimulated hexose uptake into heart, soleus and red quadriceps muscles and hIGFBP-1 partially reversed this effect. We propose that the insulin-like activity of unbound IGFs in the circulation may be regulated in vivo by fluctuating endogenous IGFBP-1 levels, so that the IGFs, along with IGFBP-1, may represent a dynamic glucoregulatory system.

Journal of Endocrinology (1993) 136, 253–260